Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Aug 17:17:1216653.
doi: 10.3389/fnins.2023.1216653. eCollection 2023.

The phenotypic presentation of adult individuals with SLC6A1-related neurodevelopmental disorders

Katrine M Johannesen  1   2 , Jimmi Nielsen  3   4 , Anne Sabers  5 , Bertrand Isidor  6 , Anja A Kattentidt-Mouravieva  7 , Dominik Zieglgänsberger  8 , Alexis R Heidlebaugh  9 , Kathryn F Oetjens  9 , Anna Abuli Vidal  10 , Jakob Christensen  11   12   13 , Jacob Tiller  14 , Amber N Freed  14 , Rikke S Møller  2   15 , Guido Rubboli  2   16
Affiliations

The phenotypic presentation of adult individuals with SLC6A1-related neurodevelopmental disorders

Katrine M Johannesen et al. Front Neurosci. .

Abstract

Introduction: SLC6A1 is one of the most common monogenic causes of epilepsy and is a well-established cause of neurodevelopmental disorders. SLC6A1-neurodevelopmental disorders have a consistent phenotype of mild to severe intellectual disability (ID), epilepsy, language delay and behavioral disorders. This phenotypic description is mainly based on knowledge from the pediatric population.

Method: Here, we sought to describe patients with SLC6A1 variants and age above 18 years through the ascertainment of published and unpublished patients. Unpublished patients were ascertained through international collaborations, while previously published patients were collected through a literature search.

Results: A total of 15 adult patients with SLC6A1 variants were included. 9/13 patients had moderate to severe ID (data not available in two). Epilepsy was prevalent (11/15) with seizure types such as absence, myoclonic, atonic, and tonic-clonic seizures. Epilepsy was refractory in 7/11, while four patients were seizure free with lamotrigine, valproate, or lamotrigine in combination with valproate. Language development was severely impaired in five patients. Behavioral disorders were reported in and mainly consisted of autism spectrum disorders and aggressive behavior. Schizophrenia was not reported in any of the patients.

Discussion: The phenotype displayed in the adult patients presented here resembled that of the pediatric cohort with ID, epilepsy, and behavioral disturbances, indicating that the phenotype of SLC6A1-NDD is consistent over time. Seizures were refractory in >60% of the patients with epilepsy, indicating the lack of targeted treatment in SLC6A1-NDDs. With increased focus on repurposing drugs and on the development of new treatments, hope is that the outlook reflected here will change over time. ID appeared to be more severe in the adult patients, albeit this might reflect a recruitment bias, where only patients seen in specialized centers were included or it might be a feature of the natural history of SLC6A1-NDDs. This issue warrants to be explored in further studies in larger cohorts.

Keywords: SLC6A1; epilepsy; epilepsy genetics; intellectual disability; neurodevelopmental disorders.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Prisma flowchart.
See this image and copyright information in PMC

Similar articles

  • Defining the phenotypic spectrum of SLC6A1 mutations.
    Johannesen KM, Gardella E, Linnankivi T, Courage C, de Saint Martin A, Lehesjoki AE, Mignot C, Afenjar A, Lesca G, Abi-Warde MT, Chelly J, Piton A, Merritt JL 2nd, Rodan LH, Tan WH, Bird LM, Nespeca M, Gleeson JG, Yoo Y, Choi M, Chae JH, Czapansky-Beilman D, Reichert SC, Pendziwiat M, Verhoeven JS, Schelhaas HJ, Devinsky O, Christensen J, Specchio N, Trivisano M, Weber YG, Nava C, Keren B, Doummar D, Schaefer E, Hopkins S, Dubbs H, Shaw JE, Pisani L, Myers CT, Tang S, Tang S, Pal DK, Millichap JJ, Carvill GL, Helbig KL, Mecarelli O, Striano P, Helbig I, Rubboli G, Mefford HC, Møller RS. Johannesen KM, et al. Epilepsia. 2018 Feb;59(2):389-402. doi: 10.1111/epi.13986. Epub 2018 Jan 8. Epilepsia. 2018. PMID: 29315614 Free PMC article.
  • Behavioral, neurodevelopmental profile, and epilepsy trajectory in two series of SLC6A1-NDD: A retrospective study with comprehensive assessment, and a participatory database study.
    Baer S, Rebert M, Burger P, Mandel JL, Villeneuve N, Gibaud M, Altuzarra C, Villega F, Cances C, Lacan L, Nguyen S, Lesca G, Isnard H, Allani-Essid N, Laugel V, Coutelle R, de Saint Martin A. Baer S, et al. Eur J Paediatr Neurol. 2025 Jan;54:121-129. doi: 10.1016/j.ejpn.2025.01.003. Epub 2025 Jan 10. Eur J Paediatr Neurol. 2025. PMID: 39889538
  • Intrafamilial variability in SLC6A1-related neurodevelopmental disorders.
    Kassabian B, Fenger CD, Willems M, Aledo-Serrano A, Linnankivi T, McDonnell PP, Lusk L, Jepsen BS, Bayat M, Kattentidt A, Vidal AA, Valero-Lopez G, Alarcon-Martinez H, Goodspeed K, van Slegtenhorst M, Barakat TS, Møller RS, Johannesen KM, Rubboli G. Kassabian B, et al. Front Neurosci. 2023 Jul 12;17:1219262. doi: 10.3389/fnins.2023.1219262. eCollection 2023. Front Neurosci. 2023. PMID: 37502687 Free PMC article.
  • Current knowledge of SLC6A1-related neurodevelopmental disorders.
    Goodspeed K, Pérez-Palma E, Iqbal S, Cooper D, Scimemi A, Johannesen KM, Stefanski A, Demarest S, Helbig KL, Kang J, Shaffo FC, Prentice B, Brownstein CA, Lim B, Helbig I, De Los Reyes E, McKnight D, Crunelli V, Campbell AJ, Møller RS, Freed A, Lal D. Goodspeed K, et al. Brain Commun. 2020 Oct 13;2(2):fcaa170. doi: 10.1093/braincomms/fcaa170. eCollection 2020. Brain Commun. 2020. PMID: 33241211 Free PMC article. Review.
  • Use of antiepileptic drugs in the treatment of epilepsy in people with intellectual disability.
    Alvarez N, Besag F, Iivanainen M. Alvarez N, et al. J Intellect Disabil Res. 1998 Dec;42 Suppl 1:1-15. J Intellect Disabil Res. 1998. PMID: 10030426 Review.
See all similar articles

Cited by

References

    1. Bain J. M., Snyder L. G., Helbig K. L., Cooper D. D., Chung W. K., Goodspeed K. (2022). Consistency of parent-report SLC6A1 data in Simons searchlight with provider-based publications. J. Neurodev. Disord. 14:40. doi: 10.1186/s11689-022-09449-7, PMID: - DOI - PMC - PubMed
    1. Borlot F., de Almeida B. I., Combe S. L., Andrade D. M., Filloux F. M., Myers K. A. (2019). Clinical utility of multigene panel testing in adults with epilepsy and intellectual disability. Epilepsia 60, 1661–1669. doi: 10.1111/epi.16273, PMID: - DOI - PubMed
    1. Carroll L. S., Woolf R., Ibrahim Y., Williams H. J., Dwyer S., Walters J., et al. . (2016). Mutation screening of SCN2A in schizophrenia and identification of a novel loss-of-function mutation. Psychiatr. Genet. 26, 60–65. doi: 10.1097/YPG.0000000000000110, PMID: - DOI - PMC - PubMed
    1. Carvill G. L., McMahon J. M., Schneider A., Zemel M., Myers C. T., Saykally J., et al. . (2015). Mutations in the GABA transporter SLC6A1 cause epilepsy with myoclonic-atonic seizures. Am. J. Hum. Genet. 96, 808–815. doi: 10.1016/j.ajhg.2015.02.016, PMID: - DOI - PMC - PubMed
    1. Fisher R. S., Cross J. H., D’Souza C., French J. A., Haut S. R., Higurashi N., et al. . (2017). Instruction manual for the ILAE 2017 operational classification of seizure types. Epilepsia 58, 531–542. doi: 10.1111/epi.13671, PMID: - DOI - PubMed

LinkOut - more resources